$CVU

CPI Aero enters the second half of 2026 with a $533M backlog

CPI Aerostructures (NYSE American: CVU) reported Q2 2026 revenue of $17.6M, up from $15.2M, with gross profit rising to $3.9M and gross margin to 22.0%. Net income was $0.7M versus a $1.3M loss. For six months, revenue was $34.9M and net income $1.9M. Backlog totaled $533M.

Original reporting
Published Aug 13, 2026, 8:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CVU
Bullish
medium confidence
Mentioned
$CVU
Relevance
7/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CVUBullishMed
01

Why it matters

The key tradable elements are the magnitude of margin expansion and the $533M backlog figure, which can influence expectations for future revenue and program execution. However, the balance sheet shows limited cash, which can constrain risk appetite if execution slips or payments lag.

02

Market read

A small-cap defense supplier delivered improved profitability and a large backlog, but liquidity remains a watch item for traders assessing risk.

03

What to watch

Funded remaining performance obligations are highlighted, but the article does not quantify cash flow from operations or working-capital swings that could drive near-term liquidity risk.

Relevance 7/10Novelty 7/10Timing: after-hours earnings release dated Aug. 13, 2026

Background

CPI Aerostructures is a DoD prime contractor and tier-1 aerospace and defense subcontractor, reporting quarterly and six-month results with backlog disclosures.

Company-level read

Ticker impact

$CVUBullishMedium confidence
Context

CPI Aerostructures reported Q2 2026 revenue of $17.6M, gross margin of 22.0%, and total backlog of $533M.

Expected impact

Near-term bias positive on backlog and margin expansion, tempered by cash balance and leverage.

Evidence & confidence

Multiple income statement improvements (revenue, gross margin, net income, adjusted EBITDA) plus a $533M backlog are supportive, while cash is only $0.84M and line of credit and debt are still meaningful.

Market effects

Supports sentiment for aerospace and defense subcontractors via evidence of improving execution and backlog conversion.

Limited, company-specific impact likely confined to small-cap defense supply chain sentiment.

Low; primarily affects US defense supply chain expectations rather than global macro.

Counterpoint

Backlog growth may not translate into near-term cash generation given the very low cash balance and ongoing debt/lease obligations.

Key entities

  • CPI Aerostructures, Inc.

    Reported Q2 and six-month 2026 results, including revenue, margins, net income, adjusted EBITDA, and $533M backlog.

  • Dorith Hakim

    CEO quoted on the company’s execution and growth strategy.

Related articles

$CVUMed

CPI AEROSTRUCTURES INC (CVU): Results of Operations and Financial Condition

CPI AEROSTRUCTURES INC (CVU) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm PRESS RELEASE, DATED AUGUST 13, 2026 CPI Aerostructures, Inc. 8-K Exhibit 99.1 CPI AEROSTRUCTURES REPORTS SECOND QUARTER AND SIX MONTH 2026 RESULTS Second Quarter 2026 vs. Second Quarter 2025 ● Revenue of $17.6 million compared to $15.2 million; ● Gross profi

$CVUMedAI 8/10

CPI Aero Secures $8.3 Million in New U.S. Air Force Orders for T-38 Aircraft Modification Kits

CPI Aerostructures (NYSE American: CVU) said the U.S. Air Force issued multiple purchase orders totaling $8.3 million for T-38 aircraft modification kits and related sustainment services under an existing IDIQ contract. Funded contract value rises to $69 million, with deliveries through 2028. CPI also cited $95 million funded backlog and $495 million total backlog.

$MPLTMed

MapLight Therapeutics, Inc. (MPLT): Results of Operations and Financial Condition

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.1 3 d48818dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is dated as of August 13, 2026, by and among MapLight Therapeutics, Inc., a Delaware corporation (the “ Company ”), and each of the purcha

$RNAMed

Atrium Therapeutics, Inc. (RNA): Results of Operations and Financial Condition

Atrium Therapeutics, Inc. (RNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d149126dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Atrium Therapeutics Reports Second Quarter 2026 Financial Results — IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome — — Achieved second milestone payment under global cardiovascular col

$CLDIMed

Calidi Biotherapeutics, Inc. (CLDI): Results of Operations and Financial Condition

Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a firs

$LOGCMed

ContextLogic Holdings Inc. (LOGC): Results of Operations and Financial Condition

ContextLogic Holdings Inc. (LOGC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 logc-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 ContextLogic Holdings Inc. Reports Second-Quarter 2026 Financial Results OAKLAND, Calif., August 13, 2026 ( GLOBE NEWSWIRE ) -- ContextLogic Holdings Inc. (OTCQB: LOGC) ("ContextLogic," the "Company," "we" or "our") today rep